Month: April 2022

TriTAC-XR demonstrates extended release mechanism that confirms accumulation of active drug which improves therapeutic index SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with preclinical data for its TriTAC-XR T cell engager platform at the American Association for Cancer Research (AACR) Annual Meeting being held in New Orleans from April 8-13, 2022. The poster titled “TriTAC-XR is an extended-release T cell engager platform that improves safety by minimizing cytokine release syndrome” showed preclinical data describing the capabilities of the novel platform in animal models. Harpoon is committed to developing best-in-class T cell engagers. TriTAC-XR, our third such platform,...

BRISBANE, Calif., April 12, 2022 (GLOBE NEWSWIRE) — Vera Therapeutics (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, announced today the appointment Michael M. Morrissey, Ph.D., as chairman of its board of directors. Dr. Morrissey has served as president and chief executive officer (CEO) of Exelixis, Inc. since July 2010. “Mike’s experience leading Exelixis’ evolution into a fully integrated biopharmaceutical company will be immensely helpful to Vera as we prepare to move from late-stage clinical programs to potential commercial growth,” said Kurt von Emster, Vera’s current chairman of the board. “We look forward to Mike’s guidance as we advance our various programs through development, engage in the regulatory...

NORWOOD, Mass., April 12, 2022 (GLOBE NEWSWIRE) — MariMed, Inc. (OTCQX: MRMD) (“MariMed” or the “Company”), a leading multi-state cannabis operator focused on improving lives every day, today announced it will report its first quarter 2022 financial results for the period ending March 31, 2022 on May 10, 2022 after the market closes. Management will host a conference call on May 11, 2022 at 8:00 a.m. EDT to discuss the results. A webcast will be available and can be accessed via MariMed’s Investor Relations website at www.ir.marimedinc.com. To listen to the live call, please visit the website at least 15 minutes early to register, download and install any necessary audio software. A playback of the call will be archived on MariMed’s website for approximately 30 days. About MariMedMariMed Inc., a multi-state cannabis operator, is...

Figure 1 Plan View of the Guayabales Project Highlighting the Apollo TargetFigure 2 Plan View of the Apollo Target Area Outlining Porphyry and Breccia Targets Overprinted by High-Grade Coincidental Copper and Molybdenum Soil AnomaliesFigure 3 Core Photos from Drill Hole APC-1 Labeled with the Down Hole Depth Where Mineralization was EncounteredTORONTO, April 12, 2022 (GLOBE NEWSWIRE) — Collective Mining Ltd. (TSXV: CNL) (“Collective” or the “Company”) is pleased to announce that the maiden drill hole to test the Apollo target (“Apollo”) is underway as part of the Company’s fully funded minimum 20,000 metre drill program for 2022 at the Guayabales project (“Guayabales”), located in Caldas, Colombia. The Company presently has four diamond drill rigs operating at Guayabales with drills currently operating at Apollo and Olympus...

– Expansion will supply clinical grade cNeT for ongoing Phase I/IIa clinical trials and support future development – LONDON, April 12, 2022 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced clinical manufacturing expansion in the United Kingdom (UK) and the United States (US). Achilles’ manufacturing facility at the Cell & Gene Therapy Catapult (Catapult) in Stevenage, UK, has received a manufacturing license from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and, separately, the Company has entered into a partnership agreement for clinical manufacturing with the Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization in King of Prussia,...

TORONTO, April 12, 2022 (GLOBE NEWSWIRE) — Clear Blue Technologies (TSXV: CBLU), the market leader in smart off-grid power technology, today announced Viasat (NASDAQ: VSAT), has selected Clear Blue’s Nano-Grid and new Pico-Grid power products to provide reliable, low-cost, clean energy solutions and management services at Viasat’s satellite-based Community Internet locations in Nigeria.   For this initiative, Clear Blue will provide its ground-breaking product, Pico-Grid. Pico-Grid uses Clear Blue’s cloud-based, smart off-grid systems and hardware architecture, designed specifically for Internet of Things (IoT) and Wi-Fi/satellite internet applications. A new product, Pico-Grid joins Clear Blue’s Illumient Smart City and Nano-Grid telecom products as the Company’s third line of innovative smart off-grid power technologies. Pico-Grid...

FORT LAUDERDALE, Fla., April 12, 2022 (GLOBE NEWSWIRE) — BurgerFi International, Inc. (NASDAQ: BFI, BFIIW) (“BurgerFi”), owner of one of the nation’s leading fast-casual “better burger” dining concepts through the BurgerFi brand, and the high-quality, casual dining pizza brand under the name Anthony’s Coal Fired Pizza & Wings (“Anthony’s”), will report financial results for the fourth quarter and full year ended December 31, 2021 on Thursday, April 14, 2022 before market hours. Management will host a conference call at 8:30 a.m. Eastern time on the same day to discuss the results.   The conference call will be broadcast live and available for replay on the Company’s Investor Relations website at ir.burgerfi.com. Participants can also access the call using the dial-in details below. Date: Thursday, April 14, 2022Time: 8:30...

TORONTO, April 12, 2022 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) is pleased to provide an update on development planning for the Valentine Gold Project located in the central region of Newfoundland and Labrador (the “Project”). In this news release, Marathon is providing guidance on remaining regulatory approvals and permitting, the Project’s execution strategy and schedule, mineral resources and mine planning, capital and operating cost outlook, and project financing. Highlights are as follows:Provincial Environmental Assessment (“EA”) completed. Federal EA approaching a ministerial decision. Site-specific permitting commenced. Subject to this regulatory schedule, site early works to commence in the third quarter, supporting full site mobilization by the end of the year and first gold...

– First patient dosed in Phase 1/2 clinical trial in ABCC6 Deficiency – – Preliminary biomarker and safety data from Phase 1/2 clinical trial in ABCC6 Deficiency expected in the second quarter of 2022 – – Second cohort in Phase 1/2 clinical trial in ENPP1 Deficiency fully enrolled; topline data expected in the second half of 2022 – BOSTON, April 12, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of INZ-701 in adult patients with ABCC6 Deficiency and the second cohort in the ongoing Phase 1/2 clinical trial in ENPP1 Deficiency has been fully enrolled. “With momentum in patient...

Lilium has submitted to EASA its proposals for how the Lilium Jet will comply with certification requirements Subject to regulatory agreement, the Means of Compliance prepares the way for the next phase of type certificationMUNICH, Germany, April 12, 2022 (GLOBE NEWSWIRE) — Lilium N.V. (NASDAQ: LILM) (“Lilium”), developer of the first all-electric vertical take-off and landing (“eVTOL”) jet, announced today that it has submitted a full set of Means of Compliance proposals to the European Union Aviation Safety Agency (“EASA”) for the type certification of the Lilium Jet. The submission to EASA represents a milestone on the path to certifying Lilium’s revolutionary eVTOL aircraft, the Lilium Jet. The Means of Compliance are an essential part of the program by which an aircraft manufacturer demonstrates a new aircraft type conforms...